StockVS

纳斯达克 · USD

Starling Oncology, Inc. (STLNW) 股票分析

Starling Oncology, Inc.(STLNW)是在纳斯达克上市的股票,以美元交易。

STLNW

$0.05

−$0.02 (−23.33%)

2026年9月4日 · 收盘

这是一只衍生品——The Oncology Institute, Inc.(STLN)普通股的认股权证。

发行人的基本面数据显示在发行人页面,而非本页。

查看STLN →

价格走势

悬停查看每日收盘价。虚线表示区间起始价。

STLNW 关键统计数据

数据截至2026年9月4日
交易
开盘价
$0.05
前收盘价
$0.07
成交量
2.01K
Beta系数股价相对大盘的波动幅度。1.0与大盘同步,高于1.0波动更大,低于1.0更小。
0.44

仅显示公司披露的指标。 数据由Yahoo Finance通过yfinance提供。每日更新。

关于Starling Oncology, Inc.

Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The company was formerly known as The Oncology Institute, Inc. and changed its name to Starling Oncology, Inc. in August 2026. Starling Oncology, Inc. was founded in 2007 and is headquartered in Cerritos, California.

公司简介以英文显示。

访问官网 →